Head of the Pluripotent Cell Technology Unit

Status: 
En estudio de elegibilidad (2º)
Deadline for submitting applications: 
Thursday, 14 October, 2021

The CNIC has been conceived to develop research of excellence, competitive and of international relevance in relation to cardiovascular diseases. The CNIC has a research center of 24,000 m2, located in Madrid, with more than 6,000 m2 for laboratories equipped with a state-of-the-art infrastructure and equipment.

CNIC is soliciting applications for an experienced and motivated scientist to direct the Pluripotent Cell Technology Technical Unit which will provide technological support and scientific services in the generation of biological models, in vivo and in vitro through genetic manipulations of mouse and human pluripotent stem cells. The technical support should cover the generation of genetically modified pigs to tackle translational research questions.

Responsibilities:

As head of the Pluripotent Cell Technology Unit the selected person will be responsible for:

-       Running the Pluripotent Cell Unit, leading a team of dedicated scientists and technicians and providing state-of-the-art human and mouse pluripotent stem cells technology to CNIC research groups.

-       Contributing to the development of CNIC strategic programs by driving innovation for human and mouse pluripotent stem cell technology in relation to cardiovascular diseases.

-       Participation in the generation of pig models of cardiovascular disease

Mandatory requirements:

  • PhD in Biological Sciences
  • At least 10 years of experience as stem cell Facility leader in a relevant industry or scientific institution.
  • Consolidated expertise in genetic modification, including CRISPR/Cas9-dependent gene editing.
  • At least 3 publications with an Impact Factor above 10 (journal´s impact factor in the year of publication) according to JCR

Valuable requirements:

  • Experience in leading, managing, and supervising core staff members and mentoring technician and researchers (it will be valued according to the number of years or fraction).  
  • Experience in generating genetically-modified mouse models and in molecular biology techniques, including sequence analysis, genetic modification design, handling of CRISPR/cas9 system to edit genome in mouse and human pluripotent stem cell (it will be valued according to the number of years or fraction).
  • Experience in in vitro modelling of human cardiovascular diseases (cell reprogramming from patient’s somatic cells) and in developing specific protocols of differentiation of stem cells into cardiovascular lineages (it will be valued according to the number of years or fraction).
  • Experience in genetic modification to generate transgenic pig models to investigate cardiovascular disease (it will be valued according to the number of years or fraction).
  • Publications in scientific journals (it will be valued according to the quantity and quality of publications).
  • Interview.

We offer:

  • Incorporation in a consolidated Research Center of international scientific relevance.
  • Access to a modern infrastructure and advanced technologies.
  • A competitive salary, commensurate with experience and qualifications.
  • Immediate incorporation
  • Permanent contract as long as the selected participant meets the legal requirements for the formalization of the contract in accordance with law.

Selection plan:

At least 3 candidates with the highest score will be interviewed (as long as they reach the minimum of 70 points in the total of the previous categories, C1-C5). The candidate with the highest score will be hired given the total score is higher than 85 points (C1-C6).

 

The CNIC is a center that advocates equal job opportunities for men and women, foreign and national, and promote nondiscrimination based on age, race or ethnic origin, religion or belief, sexual orientation, language, disability, political orientation or social or economic conditions. The CNIC ensures the utmost thoroughness in the application of the principles of equality, merit and capacity of public employment and regulations in force on data protection.

 

Evaluation criteria

C1. Experience in leading, managing, and supervising core staff members and mentoring technician and researchers in human, and mouse pluripotent stem cells technology (it will be valued according to the number of years or fraction) -25%.

C2. Experience in generating genetically modified mouse models and in molecular biology techniques, including sequence analysis, genetic modification design, handling of CRISPR/cas9 system to edit genome in mouse and human pluripotent stem cell (it will be valued according to the number of years or fraction) -25%.

C3. Experience in in vitro modelling of human cardiovascular diseases (cell reprogramming from patient’s somatic cells) and in developing specific protocols of differentiation of stem cells into cardiovascular lineages (it will be valued according to the number of years or fraction) -15%.

C4. Experience in genetic modification to generate transgenic pig models to investigate cardiovascular disease (it will be valued according to the number of years or fraction) -5%.

C5. Publications in scientific journals (it will be valued according to the quantity and quality of publications) -10%.

C6. Interview (in English)-20%

Scoring criteria: 
C1 - Experience in leading, managing, and supervising core staff members and mentoring technician and researchers in human, and mouse pluripotent stem cells technology (it will be valued according to the number of years or fraction) - 25%
C2 - Experience in generating genetically modified mouse models and in molecular biology techniques, including sequence analysis, genetic modification design, handling of CRISPR/cas9 system to edit genome in mouse and human pluripotent stem cell (it will be va - 25%
C3 - Experience in in vitro modelling of human cardiovascular diseases (cell reprogramming from patient’s somatic cells) and in developing specific protocols of differentiation of stem cells into cardiovascular lineages (it will be valued according to the numb - 15%
C4 - Experience in genetic modification to generate transgenic pig models to investigate cardiovascular disease (it will be valued according to the number of years or fraction) - 5%
C5 - Publications in scientific journals (it will be valued according to the quantity and quality of publications) - 10%
C6 - Interview (in English) - 20%

"In the event of absence of any of the evaluators an alternate evaluator of the same area will be appointed"